Candel Therapeutics Appoints Martine Zimmermann to Board

What Happened

• Candel Therapeutics (CADL) filed an 8-K on Sept. 10, 2026 announcing that its Board increased from 10 to 11 directors and unanimously appointed Martine Zimmermann, Pharm.D., effective Sept. 8, 2026.
• Dr. Zimmermann was added as a Class III director with a term expiring at the Company’s 2027 Annual Meeting of Stockholders. The Board determined she qualifies as an independent director under SEC and Nasdaq rules.
• The Company issued a press release on Sept. 10, 2026 announcing the appointment.

Key Details

• Board change: size increased from 10 to 11 on Sept. 6, 2026; appointment effective Sept. 8, 2026.
• Compensation: option to purchase 64,000 shares of common stock, vesting in equal monthly installments over three years; $40,000 annual cash retainer, paid quarterly in arrears and prorated for partial quarters.
• Background: Dr. Zimmermann is Executive VP of Regulatory Affairs & Quality Assurance at Inventiva (since Aug. 2025) and has held senior regulatory roles at Ipsen and Alexion; she serves as a director of Ligand Pharmaceuticals.
• Other: she entered the Company’s standard indemnification agreement; no related-party transactions or family relationships disclosed.

Why It Matters

• This adds independent regulatory and quality expertise to Candel’s board, which is directly relevant for a clinical-stage biopharma company navigating drug development and interactions with regulators.
• Investors should note the option grant could lead to future share issuance if exercised, and the $40,000 retainer is the cash compensation for board service.
• The filing is administrative (director appointment) rather than an operational or financial disclosure, but it affects governance and board composition, which can influence oversight of development and regulatory strategy.